Perrigo Company Upgraded to Buy

This excerpt was brought to you by Argus Research using the Research Reports feature available through Yahoo Finance Premium. Click here to start your free trial* and step up your investing.

· Perrigo Company (PRGO), a longtime leader in OTC generics, had faced pressure over the past few years from industry-wide price erosion, challenges in its animal health business, and a reduction in FDA approvals.

· But the company's prospects now appear to be changing. Pricing within the generic drug industry appears to have stabilized; management has divested the animal health business for $185 million in cash; and the company has received approval for, relaunched, and acquired the rights for several key products over the past few months.

· The company recently acquired Ranir Global Holdings LLC, the largest private label oral care company globally. It has also acquired the U.S. rights for Prevacid, a heartburn treatment, from GlaxoSmithKline. In addition, Perrigo sold its Animal Health business for $185 million.

· Given our expectation that the company will begin to show initial results from its consumer-focused transition later in the year, PRGO shares appear attractively valued at 13.1-times our 2019 EPS estimate, toward the low end of the company's five-year historical range.

Yahoo Finance Premium members can view recent Argus upgrades and downgrades by going to Research Reports and filtering by Analyst Reports.